Brief: Cara Therapeutics Announces Outcome Of Part A Of Kourage-1 Study Evaluating Oral Difelikefalin In Notalgia Paresthetica

Tvardi Therapeutics

12/06/2024 22:31

Cara Therapeutics Inc  CARA.O :
    * CARA THERAPEUTICS ANNOUNCES OUTCOME OF PART A OF KOURAGE-1
STUDY
EVALUATING ORAL DIFELIKEFALIN IN NOTALGIA PARESTHETICA
    * CARA THERAPEUTICS INC -ORAL DIFELIKEFALIN DID NOT
DEMONSTRATE
MEANINGFUL CLINICAL BENEFIT COMPARED TO PLACEBO
    * CARA THERAPEUTICS INC -COMPANY WILL DISCONTINUE CLINICAL
PROGRAM
IN NP AND EXPLORE STRATEGIC ALTERNATIVES
    * CARA THERAPEUTICS INC -AS OF MARCH 31, 2024, COMPANY HAD
APPROXIMATELY $70 MILLION IN CASH, CASH EQUIVALENTS, AND
MARKETABLE SECURITIES
    * CARA THERAPEUTICS INC -DRUG WAS GENERALLY WELL TOLERATED
WITH A
SAFETY PROFILE SIMILAR TO PRIOR TRIALS

Source text for Eikon:  ID:nGNX55Y5XK 
Further company coverage:  CARA.O